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Abstract
Background: The high prevalence of HIV-1/AIDS in areas endemic for schistosomiasis and other helminthic infections has
led to the hypothesis that parasites increase host susceptibility to immunodeficiency virus infection. We previously showed
that rhesus macaques (RM) with active schistosomiasis were significantly more likely to become systemically infected after
intrarectal (i.r.) exposure to an R5-tropic clade C simian-human immunodeficiency virus (SHIV-C) than were parasite-free
controls. However, we could not address whether this was due to systemic or mucosal effects. If systemic immunoactivation
resulted in increased susceptibility to SHIV-C acquisition, a similarly large difference in host susceptibility would be seen
after intravenous (i.v.) SHIV-C challenge. Conversely, if increased host susceptibility was due to parasite-induced
immunoactivation at the mucosal level, i.v. SHIV-C challenge would not result in significant differences between parasitized
and parasite-free monkeys.
Methods and Findings: We enrolled two groups of RM and infected one group with Schistosoma mansoni; the other group
was left parasite-free. Both groups were challenged i.v. with decreasing doses of SHIV-C. No statistically significant
differences in 50% animal infectious doses (AID50) or peak viremia were seen between the two groups. These data strongly
contrast the earlier i.r. SHIV-C challenge (using the same virus stock) in the presence/absence of parasites, where we noted a
17-fold difference in AID50 and one log higher peak viremia in parasitized monkeys (P,0.001 for both). The lack of
significant differences after the i.v. challenge implies that the increased host susceptibility is predominantly due to parasite-
mediated mucosal upregulation of virus replication and spread, rather than systemic effects.
Conclusions: The major impact of schistosome-induced increased host susceptibility is at the mucosal level. Given that
.90% of all new HIV-1 infections worldwide are acquired through mucosal contact, parasitic infections that inflame
mucosae may play an important role in the spread of HIV-1.
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Introduction
More than 20 million people in sub-Saharan Africa are infected
with HIV-1 (www.UNAIDS.org) [1]. As in the case of HIV/AIDS,
a disproportionate number of the estimated 207 million people in
the world who have schistosomiasis live in Africa. Because of the
high prevalence of schistosomiasis and soil-transmitted helminth
infections in this region and the apparent disparity of HIV-1
transmission rates compared to more industrialized countries,
parasitic worm infections have been hypothesized to contribute to
the transmission and progression of immunodeficiency virus
infections [2,3,4,5]. This hypothesis has been supported by studies
showing increased expression of HIV-1 co-receptors and elevated
viral loads in individuals with active helminth infections compared
to persons who have been successfully treated for their parasites
[6,7,8]. However, studies in humans have so far been unable to
definitely answer, or even directly address, whether schistosomiasis
and soil-transmitted helminth infections increase an individual’s
susceptibility to acquiring HIV-1.
To investigate the above hypothesis, a biologically relevant
nonhuman primate model would be useful. We previously
constructed and characterized a clade C R5 simian-human
immunodeficiency virus (SHIV-C), termed SHIV-1157ipd3N4
[9]. This virus encodes an envelope gene of the HIV-1 clade that
predominates in regions of the world where helminth infections
are highly prevalent. SHIV-1157ipd3N4 exclusively uses CCR5
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transmitted strains of HIV-1 (.90% of all new HIV-1 acquisitions
occur mucosally). Like HIV-1 infection in humans, SHIV-
1157ipd3N4 infection in rhesus macaques (RM) progresses slowly
to late disease stages [10,11,12]. We also showed that SHIV-
1157ipd3N4 was transmissible across intact rectal, vaginal and
oral mucosae and that the relative mucosal transmissibility
followed the risk order of sexual HIV-1 acquisition among
humans [12]. Therefore, SHIV-1157ipd3N4 reflects the salient
biologic features of HIV-1 transmission among humans.
Using this R5 SHIV-C model, we tested the effect of Schistosoma
mansoni infection using parasite-free and parasitized RM exposed
intrarectally (i.r.) to SHIV-C [13]. We found that the virus dose
needed to achieve viremia in 50% of the animals by the i.r. route
(i.e., the 50% animal infectious dose (AID50-i.r.)) was 17-fold lower
in RM with acute schistosomiasis compared to parasite-free
animals. However, we could not differentiate whether the
observed effects of schistosome infection on SHIV-C acquisition
were primarily the result of mucosal effects, such as inflammation
and local reactions caused by the passage of parasite eggs, or were
due to systemic effects.
To address the latter possibility, we intravenously (i.v.)
challenged schistosome-free and schistosome-infected RM with
the identical stock of SHIV-1157ipd3N4 as that used in the i.r.
study [13]. We followed a similar experimental design to
determine the minimal infectious virus dose and the AID50 for
the i.v. route (AID50-i.v.) by endpoint titration. The AID50-i.v
differed only 3.3 fold between parasite-free and S. mansoni-positive
RM, a difference that was not statistically significant. The
magnitude of this difference was much smaller than that observed
in the i.r. SHIV-C exposure study, suggesting that parasitic
infections modulate host susceptibility to lentivirus acquisition
predominantly at mucosal levels.
Materials and Methods
Virus
SHIV-1157ipd3N4 [9], a pathogenic R5-tropic SHIV-C
infectious molecular clone, is a monkey-adapted, late form of
SHIV-1157i, and encodes most of the env sequences of a primary
HIV-1 clade C strain isolated from a recently infected Zambian
infant. SHIV-1157ipd3N4 was engineered with an additional NF-
kB site per long terminal repeat (LTR) in order to enhance viral
replication. The methodology used to construct this virus and its
biology are described elsewhere [9,10,11,12]. Both the early and
late forms of our SHIV-C were pathogenic in RM, although
disease progression was somewhat slow, with AIDS developing
approximately 2.5 - 5.5 years post-inoculation [10,12].
Animals
Chinese-origin adult female RM were housed at the animal facility
of the Centers for Disease Control and Prevention (CDC) in Atlanta,
GA. This study was carried out in strict accordance with the
r e c o m m e n d a t i o n si nt h eG u i d ef o rt h eC a r ea n dU s eo fL a b o r a t o r y
Animals of the U.S. Public Health Services/National Institutes of
Health, as well as according to the recommendations in the
Weatherall report on ‘‘The Use of Non-human Primates in
Research’’ (http://www.acmedsci.ac.uk/images/project/nhpdownl.
pdf). CDC facilities are fully accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care Interna-
tional. Animal experiments were approved by the Institutional
Animal Care and Use Committees at the CDC (IACUC ID: 1522)
and the Dana-Farber Cancer Institute via a Collaborating Institution
Animal Use Agreement. Because the experiments described here
involved a virus that may cause an incurable disease, such as AIDS,
discomfort, stress and pain may occur. Animals were closely
monitored and observed for development of disease at least twice
daily. If the animals are determined to be under stress or in
discomfort, appropriate anesthetics and/or analgesics are adminis-
tered as directed by the clinical veterinary staff. Euthanasia is also an
option should treatment not alleviate stress. In the current study, no
untoward clinical problems were noted, and none of the virus-
infected monkeys progressed to AIDS. Animals were free of S. mansoni
infection at the time the study was initiated.
S. mansoni inoculation
Animals were anesthetized with ketamine and exposed
percutaneously with 500 cercariae of a Puerto Rican strain of S.
mansoni. An area on the abdomen was shaved, and cercariae were
placed within a metal ring on the skin for 30 min to allow
penetration. To monitor infection, fresh stool was obtained and
processed by formalin-ethyl acetate sedimentation and concentra-
tion. Schistosome eggs were counted microscopically. White blood
cell counts (WBC) and percent eosinophils were calculated using
standard methods. Hematology results, as well as CD4 and CD8
T-cell counts and ratios were determined by the Pathology
Laboratory of the Yerkes National Primate Research Center
(Atlanta, GA). There was no evidence of fever, diarrhea, weight
loss, or dysentery in these animals.
I.v. inoculation of virus
Anesthetized macaques were inoculated i.v. with 1 ml total
volume of various dilutions of an identical SHIV-1157ipd3N4
stock that had been grown in RM PBMC. All animals were
exposed within 1 hr after the viral stock was thawed.
Quantitation of viral RNA loads and simian cytokine
mRNAs
Peripheral blood samples were obtained by venipuncture and
collected into Vacutainer cell-preparation tubes containing sodium
citrate (Becton Dickinson, Rutherford, NJ). Immediately after
collection, plasma and PBMC were separated and quick-frozen.
Plasma samples were stored at 280uC until viral RNA loads were
assessed by real-time RT-PCR [14,15]. A quantitative real-time
Author Summary
Parasitic infections have been postulated to increase host
susceptibility to HIV-1. We previously demonstrated that
rhesus monkeys with active schistosomiasis were signifi-
cantly more likely to become systemically infected after
intrarectal exposure to an R5-tropic clade C simian-human
immunodeficiency virus then were parasite-free control
animals. However, we could not address whether parasites
exert their effect at the mucosal level or systemically. To
address the latter possibility, we measured the virus doses
needed to achieve systemic infection after intravenous
exposure of parasite-free or parasite-positive monkeys
using the identical virus stock. None of the viral
parameters tested in these two groups of monkeys were
statistically significantly different. These results suggest
that schistosomiasis modulates susceptibility to immuno-
deficiency virus acquisition predominantly at the mucosal
level. Treatment for parasitic infections in populations at
higher risk for HIV-1 acquisition could represent a cost-
effective approach to slow the spread of HIV-1, which is
predominantly transmitted through mucosal routes.
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measure total mRNA levels for the cytokines IL-2, IL-4 and IL-10
using previously described primers and protocols [28]. mRNA
expression was normalized using primers unique for the
housekeeping gene, GAPDH.
Statistical analyses
Calculation of AID50 values and statistical comparison of
infectious doses were performed using the method of Spouge [16].
Peak viral RNA loads were compared using the Wilcoxon rank-
sum test. All the reported P-values are based on two-sided testing.
Results
Determination of SHIV-C doses required for systemic
infection after i.v. challenge of naı ¨ve RM
To establish the minimum dose of virus required to systemically
infect non-parasitized control animals, seven macaques without
schistosome infection were inoculated iteratively with different doses
of virus via the i.v. route and monitored for systemic SHIV-C
infection. If an animal became successfully viremic after the first dose
of virus, the next animal was inoculated with a lower dose. Plasma
viral RNA loads were monitored using a previously published
sensitive RT-PCR method [14,15] and animals with viral loads
.10,000 copies/ml were considered to be systemically infected.
Using this procedure and statistical analysis according to the method
of Spouge [16], we determined that the AID50-i.v. in control animals
was 1 ml of a 1:151,000 dilution of the viral stock (Table 1).
Determination of SHIV-C doses required for systemic
infection after i.v. challenge of parasitized RM
First, eight RM were exposed percutaneously to 500 cercariae,
the infectious life cycle stage of schistosomes. Successful parasite
infection was confirmed by the detection of eggs in the stool
beginning at 6 weeks post-exposure (Fig. 1A). There was a
concomitant increase in eosinophils (Fig. 1A). The magnitude and
time course of infection were similar to our previous studies of
macaques infected with the same number of cercariae [13,17].
Next, peripheral blood mononuclear cells (PBMC) of parasite-
infected and control animals were isolated and analyzed for
expression of cytokines IL-2, IL-4 and IL-10. Cytokine mRNA
levels were normalized against those of the house keeping gene
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The dif-
ference in IL-4 mRNA levels before and after schistosome








6)A I D 50 95% CI
Parasite-free 51850 1:5,000 + 6.2




61542 1:50,000 + 8.4
b
DP54 1:100,000 + 21.2
b
DR13 1:100,000 + 4.8
b
60980 1:150,000 + 4.7
61891 1:250,000 – –
61535 1:500,000 – –
Median 6.2 1:151,000 1:51,900 to 1:442,000
S. mansoni
+ 51948 1:100,000 + 17.6








61951 1:500,000 + 19.3
00216 1:500,000 – –
RQ4652 1:750,000 – –
DN3P 1:1,000,000 – –
61855 1:1,500,000 – –
DP4D 1:5,000,000 – –
Median 9.0 1:521,000 1:203,000 to 1:1,340,000
(P = 0.3 parasite-free vs. S.
mansoni
+)
aThese animals were first exposed to a 1:250,000 and 1:500,000 dilution of the virus. When infection failed to occur after the initial dose, the monkeys were re-exposed
to a 1:25,000 dilution, which proved to be infective.
bInfection in these animals peaked at week 3.
cThese animals were first exposed to 1:1,000,000, 1:1,500,000 and 1:5,000,000 dilution of the virus. After infection failed to occur, the monkeys were re-exposed to
1:100,000 and 1:250,000 dilution of virus, which was infective.
Although we initially enrolled 8 RM into the two groups, 1 RM was lost during quarantine due to unrelated causes. The prior i.r. study challenge study also used 8 RM
per group [11].
doi:10.1371/journal.pntd.0001270.t001
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result confirmed the previously noted shift to a T-helper type 2
(Th2) response that is typical in acute S. mansoni infections [13,17].
After establishing active schistosomiasis, we repeated the same
iterative procedure of i.v. SHIV-C challenges described above. The
minimal infectious dose to establish systemic SHIV-C infection in
schistosome-infected animals (1:500,000) was 3.3 fold lower than
that in non-parasitized controls (1:150,000) (Table 1) (Fig. 2), but
this difference was not statistically significant. Next, we used the
method of Spouge [16] and determined that the AID50-i.v. in
parasitized RM was 1 ml of a 1:521,000 dilution of the viral stock
compared to 1 ml of a 1:151,000 dilution in parasite-free RM. This
differencewasalsonotstatisticallysignificant.Mean peakviralRNA
loads in parasitized RM with systemic SHIV-C infection after i.v.
challenge were not statistically different from those in RM without
schistosomiasis (Fig. 2, 3). In essence, none of the viral parameters
showed any statically significant differences between parasite-free
and S. mansoni-positive RM after i.v. SHIV-C challenge. This is in
stark contrast to RM challenged by the i.r. route (Fig. 2) [13]. Of
note, peak viral RNA loads observed in parasite-free RM were
similar after i.v. and i.r. SHIV-C challenges (Fig. 2).
Comparison of viral parameters between RM challenged
by the i.r. or i.v. routes in the presence or absence of
parasites
The composite data for the i.r. and i.v. challenges using the
same stock of SHIV-1157ipd3N4 in control and S. mansoni-infected
RM are shown in Table 2. As previously reported in the i.r.
challenge study [13], the AID50-i.r. was 17-fold lower in monkeys
with acute schistosomiasis compared to control RM. This
difference was highly significant (P,0.001) [13]. In contrast, in
the current i.v. challenge study, this difference was only 3.3 fold
and was not statistically significant. These data imply that the
increased host susceptibility to SHIV-C associated with schisto-
some infection is predominantly due to immunoactivation at the
mucosal level and not due to systemic effects.
Our data also allow a direct comparison of the virus doses
needed to achieve systemic infection after i.v. versus i.r. SHIV-C
challenge. In parasite-free RM, the AID50-i.r. was extrapolated to
be 24.6 ml of the undiluted virus stock. In contrast, the AID50-i.v.
was a mere 0.0034 ml (3.4 nl). We reasoned that these AID50
values are indirectly proportional to the relative risks of virus
acquisition via a given route of exposure. Thus, we converted the
AID50 values to 1/AID50 and normalized the value for the i.r.
route to 1. The ratio of 1:7,235 reflects the much greater
susceptibility of parasite-free hosts to i.v. challenge compared to
i.r. exposure. Interestingly, this ratio was much lower for S.
mansoni-infected RM (7.6:737 or 1:42). This additional measure
also reflects that S. mansoni-induced mucosal alterations preferen-
tially increase host susceptibility to SHIV-C.
Discussion
Here we showed the results of end-point titrations of an
identical SHIV-C stock as a function of the challenge route (i.v.
versus i.r.) and the presence or absence of parasites in Chinese-
origin RM. Together, our data showed: 1) the difference in AID50-
i.v. for parasite-positive vs. parasite-free RM was 3.3-fold, which
Figure 1. Infection of Chinese-origin RM with S. mansoni and IL-
4 mRNA expression levels. (A) Egg counts (per gram feces) in stool
samples collected from the S. mansoni-infected animals. Data represent
the average of three consecutive values 6 SEM. Percentage of
eosinophils was plotted as a function of time (6 SEM). (B) Ratios of
IL-4 mRNA expression relative to the expression of the housekeeping
gene (GAPDH) in PBMC before exposure to S. mansoni (week 0) and at
week 7 (before exposure to SHIV-C).
doi:10.1371/journal.pntd.0001270.g001
Figure 2. Peak viral RNA loads. Peak viral RNA loads were compared
between parasite-free and S. mansoni-infected RM in i.v and i.r.
challenge experiments. *, P = 0.004 was statistically significant after
the Bonferroni correction (since it was below 0.017). **, previously
published data were used for comparison [13]; those studies had been
performed with the identical stock of SHIV-1157ipd3N4 used here.
doi:10.1371/journal.pntd.0001270.g002
Parasites and Susceptibility to SHIV Acquisition
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AID50-i.r. for parasite-positive vs. parasite-free RM was 17-fold
(P,0.001) with very similar numbers of RM per experimental
group; and 3) peak viral RNA loads differed only among i.r.
challenged but not i.v. challenged groups of schistosome positive
vs. parasite-free RM.
The fact that the 3.3-fold difference in AID50-i.v. was not
statistically significant, whereas the difference for the AID50-i.r.
was, needs to be interpreted with caution given the constraints of
our study. Primate studies with their inherently high costs limit the
numbers of experimental animals that can be enrolled. Much
larger group sizes than we were able to use may find that
parasitized hosts challenged intravenously develop systemic
infection at statistically significantly lower viral inocula compared
to parasite-free hosts. Our current data would predict that such a
difference would be smaller than that for the mucosal virus
challenge.
Overall, our data indicate that the increased host susceptibility
to the R5 SHIV-C is predominantly due to parasite-induced
changes at the mucosal level. We postulate that host factors of the
mucosal innate and adaptive immune systems will be implicated.
The nature of our virus challenge study mandated not disturbing
the mucosa for tissue sampling. Future studies should seek to
identify the exact mechanism(s) involved in mucosally-mediated
upregulation of host susceptibility to an R5 AIDS virus in the
presence of acute S. mansoni infection.
The increased susceptibility of S. mansoni-infected monkeys to i.r.
viral exposure may be related to the passage of eggs from the
bloodstream, where the adult worms reside, to the lumen of the
gut. Egg excretion in schistosome-infected hosts is dependent on
cellular immune responses [18,19] and is thought to be facilitated
by the granulomatous response to parasite eggs [18]. As a result,
schistosomiasis is associated with increased numbers of activated T
cells in the intestinal mucosa, along with disruption of the
epithelial cell layer integrity as eggs exit the tissue. However, this
does not necessarily result in bacterial translocation and
transmission. Although a recent study in humans demonstrated
an overall increased level of lipopolysaccharides (LPS) in the
plasma of parasite-infected Kenyan individuals compared to
uninfected controls, no differences were seen when LPS levels
were compared between individuals with active egg excretion
compared to those without [20]. Similarly, we found no evidence
of elevated LPS levels in the plasma of schistosome-infected RM in
a previous study (unpublished data).
In S. haematobium infections, adult worms live in the blood vessels
surrounding the bladder instead of the intestine. Eggs are excreted
into the bladder and pass out of the host in the urine. However,
the worms can reside in other areas of the urogenital vasculature
and eggs often become lodged in other nearby organs, especially in
women, and can cause female urogenital schistosomiasis (FUS).
The latter is associated with ‘‘sandy patches’’ (yellow, grainy
areas), neovascularization, and contact bleeding of the cervix and
vaginal wall as a result of the inflammation in response to the eggs.
In studies in Zimbabwe and Tanzania, FUS was associated with a
2.7 to 4-fold higher risk of HIV-1 acquisition [4,21]. Furthermore,
the scarring of the cervix and vaginal wall caused by FUS may
increase a woman’s risk for HIV-1 infection throughout life if she
does not receive treatment at a young age [22,23]. This has led to
suggestions that treatment of schistosomiasis could be a low-cost
Figure 3. Viral RNA loads of parasite-free and S. mansoni-
infected RM after SHIV-C challenge. (A & B) viral RNA loads were
compared between parasite-free and S. mansoni-infected RM during
acute infection. During the first four weeks post-challenge, plasma
samples were analyzed weekly for viral RNA loads. The horizontal
dotted line indicates the lower limit of detection in the PCR assay (,50
viral RNA copies/ml) [14,15]. *, animals were first exposed to higher
dilution of the virus as indicated in the figure. If systemic infection failed
to occur after the initial dose, the monkeys were re-exposed to a lower
virus dilution, which proved to be infective.
doi:10.1371/journal.pntd.0001270.g003






yielding systemic infection* AID50 (ml)
Relative susceptibility to systemic
infection
(normalized)
None intrarectal 1:50 24.6 1
None intravenous 1:150,000 0.0034 7,235
S. mansoni intrarectal 1:300 1.4 17.6
S. mansoni intravenous 1:500,000 0.0019 737
*defined by plasma viral RNA load .10
4 copies/ml.
doi:10.1371/journal.pntd.0001270.t002
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Saharan Africa where this parasite is endemic.
While our primate model studies have focused on the role of
parasites in facilitating lentiviral acquisition, other investigators
have examined the role of parasites on HIV-1 disease progression.
Parasitic worms elevate viral loads and exacerbate destruction of
CD4 cells in chronic AIDS virus infection. Both studies in
experimental animals [17,24,25] and intent-to-treat studies in
people with either schistosomiasis [6] or soil-transmitted hel-
minthes [8] showed elevated viral replication in groups with active
parasitic infections compared to control groups that were never
infected with schistosomes or that had received treatment for their
worms.
Helminth infections in pregnant women, with associated higher
viral loads, may also increase the risk of mothers transmitting
HIV-1 infections to their infants [26]. The majority of maternal
HIV-1 transmissions are thought to occur intrapartum via mucosal
exposure of the fetus [27]. It is possible that parasite infection of
the mother increases the HIV-1 burden in cervico-vaginal
secretions, thereby increasing the risk of passing the virus to the
infant.
Ourcurrentstudy,togetherwithpreviousreports,clearlysuggests
that schistosomiasis increases the risk of immunodeficiency virus
acquisition predominantly at the mucosal level. While the
conclusions of our earlier intrarectal challenge study are not directly
applicable to other routes of HIV-1 exposure among humans, our
primate model data provide a proof of concept that alterations in
the mucosal environment enhance HIV-1 transmission in schisto-
some-infected hosts. Our conclusions arealsoconsistent withstudies
showing FUS as a risk factor for HIV-1 infection and the greater
role of heterosexual transmission of HIV-1 in sub-Saharan Africa
than in more industrialized countries that do not have endemic
schistosomiasis. Thus, treatment for parasitic infections in popula-
tions at high risk for HIV-1 acquisition could represent a cost-
effective approach to slow the spread of HIV-1. Furthermore,
treatment of parasites in individuals with HIV-1 coinfection could
lower viral RNA loads, which in turn would decrease the infectivity
of such persons and slow their HIV-1 disease progression.
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